Aims: To evaluate the efficacy and safety of combined therapy with sodium-glucose cotransporter 2 (SGLT-2) inhibitors plus pioglitazone versus pioglitazone alone in type 2 diabetic patients.
| INTRODUC TI ON
Type 2 diabetes mellitus is a progressive disease characterized by insulin resistance, deterioration of β-cell function and impaired glucose tolerance. 1 In the United Kingdom Prospective Diabetes Study (UKPDS), roughly 50% of newly diagnosed type 2 diabetic patients were adequately controlled with monotherapy after 3 years, which declined to only about 25% after 9 years. 2 Combination therapy of oral anti-hyperglycaemic agents appears to be a more viable strategy for improving glycaemic control.
Multiple classes of oral anti-hyperglycaemic agents are available. 3 Pioglitazone, a thiazolidinedione, increases insulin sensitivity and decreases hepatic gluconeogenesis. 4 Pioglitazone reduces the risk of cardiovascular events, 5, 6 which is important because type 2 diabetic patients are greatly burdened by cardiovascular disease. 7 However, pioglitazone has adverse effects of fluid retention, body weight gain and heart failure. 8, 9 Sodium-glucose cotransporter 2 (SGLT-2) inhibitor, a new class of oral anti-hyperglycaemic agent, increases urinary glucose excretion by inhibiting renal glucose reabsorption and facilitating net calorie loss. 10 Moreover, the mild osmotic diuresis 10 and caloric loss caused by SGLT-2 inhibitors reduce body weight, oedema and risk of heart failure.
11-13
Combining pioglitazone with an SGLT-2 inhibitor to balance fluid status and body weight might enhance glycaemic and other vascular risk factor control, while reducing side effects among type 2 diabetics. To better assess this notion, we conducted a systematic review and meta-analysis of randomized controlled trials to evaluate the efficacy (eg, glycaemic control) and safety (eg, hypoglycaemia, weight change, urinary/genital tract infection) of combined therapy with pioglitazone plus SGLT-2 inhibitors versus pioglitazone alone, in type 2 diabetic patients.
| ME THODS
The current study was conducted in accordance with the recommendations of the Preferred Reporting Items for Systematic Reviews and Meta-Analysis: the PRISMA Statement. 14 This study is exempted from IRB approval and contains no patient-level data.
| Search strategy
A systematic search was performed of PubMed, EMBASE, MEDLINE, 
| Study selection and data abstraction
We selected studies using the following entry criteria: (a) the study 
| Quality assessment
All the included studies were randomized controlled trials. Risk of bias (eg, selection bias, performance bias, detection bias, attrition bias and reporting bias) of the included trials was assessed according to the Cochrane risk of bias algorithm (https://www.cochrane.org/ training/cochrane-handbook). 15 
| Data synthesis and analysis
The efficacy end-points were HbA1c change and fasting glucose change from baseline and patients achieving Hba1C <7.0% in active vs control groups. The safety end-points were patients with hypoglycaemia, heart failure, urinary tract infection, genital tract infec- was significant with the P = 0.05 level or the I 2 statistic was >70%.
Publication bias was assessed by funnel plot if more than 10 studies were included. Sensitivity analysis was also performed to further explore the robustness of our analysis. We evaluated the quality of evidence for primary and secondary outcomes with the GRADE system. 15 We used the software, Review Manager Software Package (RevMan version 5.3, The Cochrane Collaboration, London, UK), for meta-analysis.
| RE SULTS
The literature review identified 14 full articles for detailed assessment, of which nine were excluded for comparison between SGLT-2 and pioglitazone (k = 2), comparison between SGLT-2 and placebo (k = 6) or comparison between GLP-1 receptor agonist plus pioglitazone and insulin (k = 1). Our final analysis included five articles derived from four randomized controlled trials ( Figure S1 ). [16] [17] [18] [19] [20] The SGLT-2 inhibitors used in the included trials were four different SGLT-2 inhibitors. [16] [17] [18] [19] All included studies had run-in period before the experiment started, and finally, a total of 1411 individuals were enrolled. The mean age was 55.2 years old and 44.9% were women.
The baseline characteristics of the included studies are summarized in Table 1 . About 938 participants were randomly assigned to the active group which received SGLT-2 inhibitor and background treat- Table S1 .
| Efficacy end-points
The assessment of the quality of a body of evidence for all end-points is shown in Table S2 .
Pooling data from included trials showed that Hba1C reduction was larger in both low-dose SGLT-2 inhibitors plus pioglitazone (mean difference: −0.59%, 95% CI: −0.77 to −0.41%, P < 0.001) and high-dose SGLT-2 inhibitors plus pioglitazone (mean difference:
−0.65%, 95% CI: −0.78 to −0.53%, P < 0.001) than pioglitazone alone in 24-26 weeks ( Figure 1A ). The quality of a body of evidence was found to be low (low-dose) to moderate (high-dose). We conducted 
TA B L E 1 Continued sensitivity analysis and heterogeneity was not noted after excluding
SPOTLIGHT trial, which related to more substantial HbA1c reduction. There was no substantial publication bias on funnel plot ( Figure   S2 ). The efficacy of Hba1c reduction was sustained to extension period (48-76 weeks; Figure S2A ).
Pooling data from included trials showed that more patients with use of SGLT-2 inhibitor plus pioglitazone than use of pioglitazone in achieving Hba1C <7% (37.5% vs 17.5%; OR: 3.21, 95% CI: 1.99 to 5.16, P < 0.001), and there was no heterogeneity among trials (P = 0.22; Figure 1B ). The quality of a body of evidence was found to be moderate and additional 230 per 1000 diabetic patients treated with SGLT-2 inhibitor plus pioglitazone compared with pioglitazone alone would achieve Hba1c <7%.
Pooling data from included trials showed fasting glucose reduction was larger in both low-dose SGLT-2 inhibitor plus pioglitazone Figure 1C ). The quality of a body of evidence was found to be low. The efficacy of fasting glucose reduction was sustained to extension period (48-76 weeks; Figure S2B ).
F I G U R E 1 Glycaemic control efficacy:
A, HbA1c change from baseline; B, participants achieved Hba1c <7%; C, fasting glucose change from baseline in an SGLT-2 inhibitor plus pioglitazone vs pioglitazone at 24-26 weeks Heterogeneity was observed among low-dose SGLT-2 inhibitor plus pioglitazone vs pioglitazone in end-points of Hba1C change (I 2 = 65%) and fasting glucose change (I 2 = 78%), probably due to stronger glucose reducing effect of ipragliflozin. Heterogeneity disappeared when we excluded SPOTLIGHT study (I 2 = 18% for Hba1c change, I 2 = 50% for fasting glucose change).
F I G U R E 2
Safety assessments: A, risk of hypoglycaemia; B, urinal tract infection; C, genital tract infection; D, death rate; E, heart failure; in an SGLT-2 inhibitor plus pioglitazone vs pioglitazone
| Safety end-points
Pooling results from the included trials showed that SGLT-2 inhibitor plus pioglitazone compared with pioglitazone did not increase risk of hypoglycaemia (OR: 1.08, 95% CI: 0.30 to 3.89, P = 0.91; Figure 2A) or urinal tract infection (OR: 0.87, 95% CI: 0.59 to 1.26, P = 0.46; Figure 2B ) but did increase genital tract infection (OR: 4.04, 95%
CI: 2.09 to 7.81, P < 0.001; Figure 2C ). The death rate was not F I G U R E 3 Body weight and blood pressure change from baseline: A, body weight change; B, systolic blood pressure change; C, diastolic blood pressure change in an SGLT-2 inhibitor plus pioglitazone vs pioglitazone significantly different between active group and control group (OR:
1.15, 95% CI: 0.17 to 7.88, P = 0.89; Figure 2D ). The heart failure was not significantly different between active group and control group (OR: 0.50, 95% CI: 0.05 to 4.78, P = 0.54; Figure 2E ). The quality of a body of evidence was found to be low to moderate.
| Body weight and blood pressure change
At the short-term core period, pooling data from included trials showed that both low-dose and high-dose SGLT-2 inhibitors plus pioglitazone were associated with larger weight change than pioglitazone alone (low-dose: mean difference: −2.22 kg, 95% CI −2.67 to −1.77 kg, P < 0.001; high-dose: mean difference: −2.27 kg, 95% CI −3.36 to −1.17 kg, P < 0.001; Figure 3A) . Heterogeneity was noted in high-dose SGLT-2 inhibitors (P = 0.001). The quality of a body of evidence was found to be low. The body weight reduction was sustained to extension period ( Figure S3A ).
Pooling data from included trials showed that both low-dose 
| D ISCUSS I ON
In this meta-analysis comprising 4 randomized controlled trials with more than 1400 type 2 diabetic patients, we found SGLT-2 inhibitors added on to pioglitazone were more efficacious in controlling blood glucose than pioglitazone alone, as shown with several indices of better glycaemic control such as HbA1c reduction, lower fasting glucose and percentage of participants achieving HbA1c <7%. Also, SGLT-2 inhibitor as add-on therapy to pioglitazone vs pioglitazone, reduced weight and blood pressure. The risks of death, heart failure, hypoglycaemia and urinary tract infection were not different between active and control groups, although genital tract infection was more frequently seen in active group. These results were consistent at 24-26 weeks and 48-72 weeks.
Although metformin is widely accepted as the first line of oral hypoglycaemic drug for type 2 diabetes mellitus, 21 the number of patients who achieve the target glucose level with a single oral antihyperglycaemic agent decreases as type 2 diabetes mellitus progresses. 2 Combination therapy of anti-hyperglycaemic drugs is often necessary to achieve glycaemic goal.
Our meta-analysis showed that compared to pioglitazone alone, SGLT-2 inhibitor plus pioglitazone was associated with sustained glycaemic control, without increasing risk of hypoglycaemia.
Hypoglycaemia due to anti-hyperglycaemic drugs causes significant morbidity and occasional mortality, limiting maintenance of euglycaemia. 22 A meta-regression analysis suggested that HbA1c reduction was significantly associated with a decreased risk of major cardiovascular events. 23 Furthermore, an anti-hyperglycaemic drug, which improves cardiovascular outcomes, is considered to be the therapeutic agent of choice. 24, 25 Both pioglitazone and SGLT-2 are associated with reduction of major cardiovascular events. 6, 13, 26 Pioglitazone, an insulin sensitizer agent, might slow down, or even reverse, the atherosclerotic process, thus reducing myocardial infarction and stroke, [27] [28] [29] and the benefits of pioglitazone are most prominent in diabetic patients with established cardiovascular disease or stroke.
30,31
On the other hand, SGLT-2 inhibitors reduce major cardiovascular events, mainly through reducing cardiovascular death. 13, 26 SGLT-2 inhibitors also substantially reduced heart failure. 13, 26 Heart failure may play a role in the mortality of patients with coronary artery disease, and reduced risk of death through heart failure may provide at least one mechanism to explain the reduced risk of cardiovascular death with SGLT-2 inhibitors. 29 Also, our meta-analysis showed that SGLT-2 inhibitors plus pioglitazone vs pioglitazone reduced systolic/ diastolic blood pressure by 3-4/2-3 mm Hg which might also be beneficial for diabetic patients. Taking all of this together raises the possibility that the combination of metformin, pioglitazone and a SGLT-2 inhibitor might be additive, with regard to reducing, cardiovascular risk in people with diabetes at high cardiovascular risk.
29
Pioglitazone was found to increase the risk of heart failure, probably due to fluid retention, and increased body weight.
6,32
On the other hand, osmotic diuresis caused by SGLT-2 inhibitors leads to mild volume depletion and total caloric loss related to urinary glucose excretion participates. 11 Our study suggested that combination therapy with SGLT-2 inhibitor and pioglitazone significantly reverses the side effect of body weight gain caused by pioglitazone. Also, moderate weight loss has been shown to help fasting blood glucose control, 33 and such benefits can be achieved through long-term combination therapy with SGLT-2 inhibitor and pioglitazone. Moreover, since main composition of reduced body weight caused by SGLT-2 inhibitor was fat mass, rather than muscle mass, 34 it would not cause additional problem of fragility.
Although the current meta-analysis did not assess end-point of heart failure due to such information not provided by included trials, it is plausible that combination of SGLT-2 inhibitor and pioglitazone would have fewer heart failure than pioglitazone since SGLT-2 inhibitors have been shown to substantially reduce heart failure in large clinical trials. 13, 26, 35 for diabetic control by only through oral anti-hyperglycaemic drugs.
Our study has limitations. First, meta-analysis may be biased when the literature search fails to identify all relevant trials. To minimize these risks, we performed thorough searches across multiple literature and trial databases and used explicit criteria for study selection, data abstraction and data analysis. Second, sample size was moderate in all included trials, and no end-point of major cardiovascular events was assessed. Also, the individuals with previous cardiovascular disease were excluded from included trials. Whether combination of SGLT-2 inhibitor and pioglitazone has beneficial effects on cardiovascular outcomes, especially in patients with high cardiovascular risk,
was not known in the current meta-analysis. Third, the quality of a body of evidence was found to be low to moderate in most end-points.
In conclusion, in this meta-analysis of randomized controlled trials comparing an SGLT-2 inhibitor plus pioglitazone vs pioglitazone, we found that an SGLT-2 inhibitor plus pioglitazone was associated with better glycaemic control, and reduced body weight and blood pressure, without any increase in hypoglycaemia, death or urinary tract infection. However, genital tract infection increased with combination therapy. Large randomized controlled trials might be warranted to evaluate whether such combination therapy is beneficial for cardiovascular outcomes in diabetic patients with high cardiovascular risks.
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